213 results
To compare the feasibility of mutation analysis in samples obtained with EUS-FNA and EUS-TCB in patients with mediastinal lymph node metastasis in NSCLC. To compare EUS-TCB with EUS-FNA in diagnosing benign and malignant mediastinal disease.
To determine whether SRT achieves a local control rate comparable to surgery in patients with metastatic lung disease.
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
Primary Objective: The primary objective is to investigate whether EUS-TCB had an added value on EUS-FNA alone. Secondary Objective(s): The secondary objective is to study whether EUS-TCB does not have a higher complication rate than EUS-FNA alone.
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine.
(1) Investigate diagnostic performance (sensitivity) of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to standard WLB for detecting abnormalities of the tracheobronchial tree. Furthermore we aim to…
To determine whether CT-PET virtual bronchoscopy guided TBNA (CT-PET-VB guided TBNA) is suitable for staging MLNs in patients with suspected LC.
Feasibility of PET probe guided extirpation of FDG-PET positive lymph nodes which are negative on other imaging modalities in head and neck cancer patients scheduled for primary irradiation.
to evaluate the role of thoracic irradiation in patients with ED-SCLC who respond to chemotherapy and to assess the effect on 1 year survival
• To study the effect of treatment modalities immunotherapy (anti-PD1 or anti-PDL-1), and targeted therapy (crizotinib, gefitinib or erlotinib) on the size and diversity of lung carcinoma-specific T cell populations as measured by immune assays,…
To determine long-term outcome of patients with advanced non-squamous NSCLC harbouring at diagnosis EGFR mutations with and without T790M mutation and treated with the combination of erlotinib and bevacizumab.
The main aim of this study is to explore the recovery of physical and psychological health status, and HRQoL simultaneously in lung cancer patients that have undergone lung resection in the Netherlands. Next to that, we hope to identify the…
To evaluate the efficacy of the drug combination. Translational work is aimed to explore pharmacodynamic, predictive and surrogate endpoint biomarkers in tumor tissue and blood.
This study is important in that not only will we learn information about the true oncologic differences between these therapies, we will also determine the relative impact of these therapies on pulmonary function and quality of life.
see whether this treatment schedule is effective in EGFR-mutated NSCLC patients who have developed progression after treatment with EGFR-TKI monotherapy in standard dose before
2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…
Primary objective* To estimate efficacy for each study stratum at 18 weeks as assessed by RECISTKey Secondary objectives:* To estimate overall survival (OS) and progression free survival (PFS) in patients with advanced NSCLC* To determine safety and…
To assess the efficacy of combined treatment with sorafenib and metformin.
Hypothesis: Fiducial markers implanted in mediastinal lymph nodes by EUS-FNA or EBUS will show inter and intra-fraction lymph node position variability on 4D-(CB) CT-scansObjective: To quantify respiratory induced mediastinal lymph node motion and…
To define the recommended phase II mean*lung dose (MLD) to treat peripheral stage II or III NSCLC using SABR for the primary tumor and CFRT for the mediastinal lymph nodes while given concurrent chemotherapy.